NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 59 filers reported holding NEUROCRINE BIOSCIENCES INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $1,114,000 | 0.0% | 900,000 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $1,114,000 | +47.5% | 900,000 | +50.0% | 0.00% | – |
Q3 2021 | $755,000 | -5.3% | 600,000 | 0.0% | 0.00% | – |
Q2 2021 | $797,000 | -1.2% | 600,000 | 0.0% | 0.00% | – |
Q1 2021 | $807,000 | +94.9% | 600,000 | +100.0% | 0.00% | – |
Q4 2020 | $414,000 | +0.2% | 300,000 | 0.0% | 0.00% | – |
Q3 2020 | $413,000 | -63.0% | 300,000 | -55.4% | 0.00% | -100.0% |
Q2 2020 | $1,117,000 | +86.8% | 672,000 | +43.9% | 0.00% | 0.0% |
Q1 2020 | $598,000 | -16.4% | 467,000 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $715,000 | -55.6% | 467,000 | -60.3% | 0.00% | 0.0% |
Q3 2019 | $1,609,000 | -26.8% | 1,175,000 | -29.9% | 0.00% | -50.0% |
Q2 2019 | $2,198,000 | +14.5% | 1,675,000 | +18.0% | 0.00% | 0.0% |
Q1 2019 | $1,919,000 | +436.0% | 1,420,000 | +373.3% | 0.00% | – |
Q4 2018 | $358,000 | -73.7% | 300,000 | -62.5% | 0.00% | -100.0% |
Q3 2018 | $1,363,000 | -46.0% | 800,000 | -54.3% | 0.00% | -50.0% |
Q2 2018 | $2,526,000 | – | 1,750,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aequim Alternative Investments LP | 24,000,000 | $30,877,000 | 5.11% |
Alken Asset Management Ltd | 360,000 | $457,000 | 1.90% |
III Capital Management | 3,500,000 | $4,481,000 | 1.64% |
SHENKMAN CAPITAL MANAGEMENT INC | 3,920,000 | $5,113,000 | 0.76% |
CSS LLC/IL | 6,842,000 | $8,745,000 | 0.69% |
DeepCurrents Investment Group LLC | 10,408,000 | $13,373,000 | 0.65% |
SSI INVESTMENT MANAGEMENT LLC | 4,334,000 | $5,554,000 | 0.49% |
WOLVERINE ASSET MANAGEMENT LLC | 18,250,000 | $23,476,000 | 0.34% |
MACKAY SHIELDS LLC | 24,612,000 | $31,641,000 | 0.29% |
Nicholas Investment Partners, LP | 1,115,000 | $1,429,000 | 0.28% |